Parthenolide inhibits the tumor characteristics of renal cell carcinoma

  • Authors:
    • Dandan Liu
    • Yanyan Han
    • Lei Liu
    • Xinxiu Ren
    • Han Zhang
    • Shujun Fan
    • Tao Qin
    • Lianhong Li
  • View Affiliations

  • Published online on: November 16, 2020     https://doi.org/10.3892/ijo.2020.5148
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Parthenolide has been demonstrated to have anticancer effects against various types of cancer. However, the functional role of parthenolid has yet to be clearly reported in renal cell carcinoma (RCC). The aim of the present study was to investigate the effect of parthenolide in RCC 786‑O and ACHN cells. CCK‑8 and colony‑formation assays were used to observe the proliferation of RCC 786‑O and ACHN cells. Migration and invasion abilities were assessed through Transwell assays. The stem cell‑like properties of RCC cell lines were evaluated by mammosphere formation assay. Western blot analysis was used to investigate the metastasis and epithelial‑mesenchymal transition (EMT) induced by parthenolide on the expression levels of MMP2, MMP9, E‑cadherin, N‑cadherin, vimentin and snail. The results revealed that when the cells were treated with various concentrations of parthenolide, the rate of proliferation and growth was decreased in 786‑O and ACHN cells. The number of invasive cells in a field was approximately 170, 90, 40 and 190, 150, 70 in 786‑O and ACHN cells with 0, 4 and 8 µM of parthenolide treatment. MMP‑2/‑9 expression (P<0.05) was inhibited by parthenolide. The protein levels of E‑cadherin were increased (P<0.05) and N‑cadherin, vimentin and snail were decreased (P<0.05) by parthenolide treatment. In addition, Parthenolide inhibited the expression of cancer stem cell markers and the PI3K/AKT pathway. The present study confirmed that parthenolide inhibited RCC cell proliferation and metastasis and suppressed the stem cell‑like properties of RCC cell lines, which could be a potential strategy to treat RCC. However, further molecular mechanisms of parthenolide in RCC should be observed and reported in the future.

Related Articles

Journal Cover

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu D, Han Y, Liu L, Ren X, Zhang H, Fan S, Qin T and Li L: Parthenolide inhibits the tumor characteristics of renal cell carcinoma. Int J Oncol 0: 0-0, 1899
APA
Liu, D., Han, Y., Liu, L., Ren, X., Zhang, H., Fan, S. ... Li, L. (1899). Parthenolide inhibits the tumor characteristics of renal cell carcinoma. International Journal of Oncology, 0, 0-0. https://doi.org/10.3892/ijo.2020.5148
MLA
Liu, D., Han, Y., Liu, L., Ren, X., Zhang, H., Fan, S., Qin, T., Li, L."Parthenolide inhibits the tumor characteristics of renal cell carcinoma". International Journal of Oncology 0.0 (1899): 0-0.
Chicago
Liu, D., Han, Y., Liu, L., Ren, X., Zhang, H., Fan, S., Qin, T., Li, L."Parthenolide inhibits the tumor characteristics of renal cell carcinoma". International Journal of Oncology 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ijo.2020.5148